{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-006234","form_type":"8-K","ticker":"RXST","cik":"0001111485","company_name":"RxSight, Inc.","filed_at":"2023-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.900020+00:00","generated_at":"2026-06-18T11:08:31.278882+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"RxSight Q4 revenue $16.1M (+91% YoY); FY22 revenue $49.0M (+117%); guides FY23 rev $78-83M","bullets":["Q4 2022 revenue $16.1M, up 91% YoY; LAL procedure volumes up 208% to 9,123 units; LDD installed base 400 (+94% YoY).","Full year 2022 revenue $49.0M, up 117% YoY; sold 195 LDDs and 25,284 LALs.","FY23 revenue guidance $78-83M (59-69% growth); gross margin guidance 52-54% (up from 43.5% in FY22).","Net loss Q4 $(15.6)M ($0.56 loss per share); adjusted net loss $(12.6)M ($0.45 loss per share).","Completed public offering of 4.6M shares (including underwriter option) at $12.50/share in Feb 2023, raising ~$57.5M gross."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-006234","json":"https://secwatch.observer/filing/0000950170-23-006234.json","markdown":"https://secwatch.observer/filing/0000950170-23-006234.md","text":"https://secwatch.observer/filing/0000950170-23-006234.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1111485/000095017023006234/0000950170-23-006234-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1111485/000095017023006234/rxst-20230306.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T11:08:31.278882+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ebb743f1b7f68e6625190d2b9eb89a079db43868","claim":"RxSight, Inc. reported the three and twelve-months ended December 31, 2022 results: revenue $16.1 million, net income $(15.6) million, EPS $(0.56) per basic and diluted share. Guidance initiated.","evidence_excerpt":"today reported financial results for the three months and full year ended December 31, 2022. Key Quarterly and Full Year Highlights • Recognized fourth quarter 2022 revenue of $16.1 million, an increase of 91% compared to the fourth quarter of 2021, reflecting: • The sale of 57 Light Delivery Devices (LDDTMs), representing a 27% unit increase from the fourth quarter","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1111485/000095017023006234/0000950170-23-006234-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and twelve-months ended December 31, 2022"},{"label":"Revenue","value":"$16.1 million"},{"label":"Net income","value":"$(15.6) million"},{"label":"EPS","value":"$(0.56) per basic and diluted share"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}